Editas Medicine presents preclinical data on gene editing at ASGCT, aiming to develop candidates for hematopoietic and liver therapies by 2025. Editas Medicine, Inc. announced its progress in the ...

Beam Therapeutics has presented the first clinical data on its base editing technology. All four sickle cell disease patients in the efficacy cohort had fetal hemoglobin levels above Beam’s target—and ...

Gene editing is growing up. Ten years after Science magazine named CRISPR its 2015 “Breakthrough of the Year,” this revolutionary gene editing technology has become a workhorse of modern biology. In ...

Why Data Confidentiality in Essay Editing Matters More Than Ever in the U.S. In today’s digital age, the demand for professional academic assistance has surged, making essay editing services ...

Companies developing RNA-editing therapies are rallying Wednesday after breakthrough data from a clinical trial showed the technology’s promise as a treatment. Wave Life Sciences Ltd. said it achieved ...

Verve Therapeutics has published the first data on an in vivo base editing program in humans, giving the world an early look at the effects of a cholesterol-busting candidate that could become part of ...

The Cambridge-based base editing company, Beam Therapeutics, has announced initial safety and efficacy data from its Phase I/II trial of BEAM-302, establishing clinical proof-of-concept as a potential ...

LEIDEN, Netherlands & CAMBRIDGE, Mass., July 06, 2023 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies ...

The company stated that 62% of the patients in the trial who received lonvo-z were entirely free of HAE attacks during the six-month evaluation period, compared to 11% of patients who received placebo ...